Authors
Guangshuo Gan, Xiaonan Zhang, Yao Xu, Kunling Bai, Xiangyun Yan, Deshi Dong, Hong Xiang, Xufeng Tao
Published in
Drug design, development and therapy. Volume 20. Pages 610190. Epub Jun 18, 2026.
Abstract
Peptides have emerged as pivotal agents in biomedicine due to their exceptional physicochemical properties, including high binding affinity, minimal immunogenicity, and precise target specificity. This review critically examines recent advancements in peptide-based strategies for pancreatic disorders, encompassing inflammatory conditions (e.g. pancreatitis), metabolic dysfunctions (e.g. diabetes), and notably, pancreatic cancer. We delineate the evolution of peptide therapeutics, emphasizing rational drug design approaches such as backbone cyclization and N-methylation to enhance metabolic stability, complemented by computational methodologies like molecular docking and AI-driven affinity maturation to optimize target engagement. The discussion highlights key innovations, including peptide probes for early diagnostic detection and peptide-drug conjugates for targeted intervention, while evaluating their efficacy in preclinical models and assessing their biosafety profiles. Furthermore, we survey current clinical trials aimed at translating these engineered peptides into clinical applications. Concluding with a perspective on precision medicine, we outline future trajectories necessitating advanced AI-integrated design frameworks and robust clinical validation to accelerate the bench-to-bedside translation of peptide technologies.
PMID:
42338763
Bibliographic data and abstract were imported from PubMed on 24 Jun 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 7
- Comments 0